These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept. Blindbæk SL; Peto T; Grauslund J Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608 [TBL] [Abstract][Full Text] [Related]
24. Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions. Hanhart J; Rozenman Y Ophthalmologica; 2017; 238(1-2):110-118. PubMed ID: 28535531 [TBL] [Abstract][Full Text] [Related]
25. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM; JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687 [TBL] [Abstract][Full Text] [Related]
26. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs. Ibrahim WS; Eldaly ZH; Saleh MG; Rateb MF; Aldoghaimy AH Korean J Ophthalmol; 2019 Apr; 33(2):122-130. PubMed ID: 30977321 [TBL] [Abstract][Full Text] [Related]
27. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections. Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890 [TBL] [Abstract][Full Text] [Related]
28. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion. Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163 [TBL] [Abstract][Full Text] [Related]
29. One-Year Functional and Morphological Prognosis After Intravitreal Injection Treatments According to Different Morphological Patterns of Diabetic Macular Edema in Real-Life: MARMASIA Study Group Report No.13. Limon DU; Kaplan FB; Saygın I; Önder Tokuç E; Kutlutürk Karagöz I; Kanar HS; Sevik MO; Yayla U; Çelik E; Sönmez A; Aykut A; Kumral Türkseven E; Erçalık NY; Oncu Aydın Ö; Bozkurt E; Aydoğan T; Emengen EB; Özkaya A; Açıkalın Öncel B; Yenerel NM; Şahin Ö; Karabaş L Semin Ophthalmol; 2024 Aug; 39(6):460-467. PubMed ID: 39087722 [TBL] [Abstract][Full Text] [Related]
30. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756 [TBL] [Abstract][Full Text] [Related]
31. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448 [TBL] [Abstract][Full Text] [Related]
32. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema. Felfeli T; Juncal VR; Hillier RJ; Mak MYK; Wong DT; Berger AR; Kohly RP; Kertes PJ; Eng KT; Boyd SR; Altomare F; Giavedoni LR; Muni RH Am J Ophthalmol; 2019 Oct; 206():176-183. PubMed ID: 30959004 [TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915 [TBL] [Abstract][Full Text] [Related]
34. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits. Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606 [TBL] [Abstract][Full Text] [Related]
35. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema. Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365 [TBL] [Abstract][Full Text] [Related]